High levels of sulphadoxine-pyrimethamine resistance Pfdhfr-Pfdhps quintuple mutations: A cross sectional survey of six regions in Tanzania

Malaria Journal

Volumn 13, Issue 1, 2014, Pages

  Matondo, Sungwa I ^a   Temba, Godfrey S ^a   Kavishe, Adelaida A ^a,b   Kauki, Julius S ^a   Kalinga, Akili ^c   Van Zwetselaar, Marco ^a   Reyburn, Hugh ^a,d   Kavishe, Reginald A ^a  

^a KILIMANJARO CHRISTIAN MEDICAL UNIVERSITY COLLEGE   (Tanzania)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^c NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (Tanzania)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; PYRIMETHAMINE PLUS SULFADOXINE;

ADULT; ANTIMALARIAL DRUG RESISTANCE; ARTICLE; CODON; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC TEST; DNA EXTRACTION; FEMALE; GENE MUTATION; GENOTYPE; GROUPS BY AGE; HAPLOTYPE; HEALTH CARE FACILITY; HEALTH SURVEY; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MIXED INFECTION; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; PRICK TEST; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TANZANIA;

ADULT; ANTIMALARIALS; CHILD; CROSS-SECTIONAL STUDIES; DIHYDROPTEROATE SYNTHASE; DRUG COMBINATIONS; DRUG RESISTANCE; FEMALE; HUMANS; MALARIA, FALCIPARUM; MALE; MUTATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PREGNANCY; PROTOZOAN PROTEINS; PYRIMETHAMINE; SULFADOXINE; TANZANIA; TETRAHYDROFOLATE DEHYDROGENASE;

EID: 84899587485     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-13-152     Document Type: Article

References (38)

1. Tanzania phases out chloroquine for the treatment of malaria. Taverne J, Trends Parasitol 2001 17 360
2. Patterns of resistance and DHFR/DHPS genotypes of Plasmodium falciparum in rural Tanzania prior to the adoption of sulfadoxine-pyrimethamine as first-line treatment. Eriksen J, Mwankusye S, Mduma S, Kitua A, Swedberg G, Tomson G, Gustafsson LL, Warsame M, Trans R Soc Trop Med Hyg 2004 98 347 353 10.1016/j.trstmh.2003.10.010 15099990 (Pubitemid 38950393)
3. In vivo efficacy study of amodiaquine and sulfadoxine/ pyrimethamine in Kibwezi, Kenya and Kigoma, Tanzania. Gorissen E, Ashruf G, Lamboo M, Bennebroek J, Gikunda S, Mbaruku G, Kager PA, Trop Med Int Health 2000 5 459 463 10.1046/j.1365-3156.2000.00570.x 10929148 (Pubitemid 30469983)
4. The costs of introducing artemisinin-based combination therapy: evidence from district-wide implementation in rural Tanzania. Njau JD, Goodman CA, Kachur SP, Mulligan J, Munkondya JS, McHomvu N, Abdulla S, Bloland P, Mills A, Malar J 2008 7 4 10.1186/1475-2875-7-4 18179716 (Pubitemid 351313746)
5. Malaria prevention with IPTp during pregnancy reduces neonatal mortality. Menendez C, Bardaji A, Sigauque B, Sanz S, Aponte JJ, Mabunda S, Alonso PL, PLoS One 2010 5 9438 10.1371/journal.pone.0009438 20195472
6. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birthweight in rural Malawi. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Russell WB, Broadhead RL, Ann Trop Med Parasitol 1998 92 141 150 10.1080/00034989859979 9625909 (Pubitemid 28140462)
7. Malaria in pregnancy and its consequences for the infant in rural Malawi. Verhoeff FH, Brabin BJ, Chimsuku L, Kazembe P, Broadhead RL, Ann Trop Med Parasitol 1999 93 Suppl 1 25 S33 10715686
8. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of September 2012 meeting. WHO-MPAC, Malar J 2012 11 424 23253143
9. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: a randomised, double-blind, placebo-controlled trial. Gosling RD, Gesase S, Mosha JF, Carneiro I, Hashim R, Lemnge M, Mosha FW, Greenwood B, Chandramohan D, Lancet 2009 374 1521 1532 10.1016/S0140-6736(09)60997-1 19765815
10. Protective efficacy of intermittent preventive treatment of malaria in infants (IPTi) using sulfadoxine-pyrimethamine and parasite resistance. Griffin JT, Cairns M, Ghani AC, Roper C, Schellenberg D, Carneiro I, Newman RD, Grobusch MP, Greenwood B, Chandramohan D, Gosling RD, PLoS One 2010 5 12618 10.1371/journal.pone.0012618 20838642
11. Intermittent treatment to prevent pregnancy malaria does not confer benefit in an area of widespread drug resistance. Harrington WE, Mutabingwa TK, Kabyemela E, Fried M, Duffy PE, Clin Infect Dis 2011 53 224 230 10.1093/cid/cir376 21765070
12. Allelic exchange at the endogenous genomic locus in Plasmodium falciparum proves the role of dihydropteroate synthase in sulfadoxine-resistant malaria. Triglia T, Wang P, Sims PF, Hyde JE, Cowman AF, EMBO J 1998 17 3807 3815 10.1093/emboj/17.14.3807 9669998 (Pubitemid 28333967)
13. Sulfadoxine resistance in the human malaria parasite Plasmodium falciparum is determined by mutations in dihydropteroate synthetase and an additional factor associated with folate utilization. Wang P, Read M, Sims PF, Hyde JE, Mol Microbiol 1997 23 979 986 10.1046/j.1365-2958.1997.2821646.x 9076734 (Pubitemid 27096733)
14. High resistance of Plasmodium falciparum to sulphadoxine/pyrimethamine in northern Tanzania and the emergence of dhps resistance mutation at Codon 581. Gesase S, Gosling RD, Hashim R, Ord R, Naidoo I, Madebe R, Mosha JF, Joho A, Mandia V, Mrema H, Mapunda E, Savael Z, Lemnge M, Mosha FW, Greenwood B, Roper C, Chandramohan D, PLoS One 2009 4 4569 10.1371/journal.pone.0004569 19238219
15. Five years of antimalarial resistance marker surveillance in Gaza Province, Mozambique, following artemisinin-based combination therapy roll out. Raman J, Mauff K, Muianga P, Mussa A, Maharaj R, Barnes KI, PLoS One 2011 6 25992 10.1371/journal.pone.0025992 22022487
16. Rapid and effective processing of blood specimens for diagnostic PCR using filter paper and Chelex-100. Polski JM, Kimzey S, Percival RW, Grosso LE, Mol Pathol 1998 51 215 217 10.1136/mp.51.4.215 9893748 (Pubitemid 28394271)
17. High prevalence of mutations in the dihydrofolate reductase gene of Plasmodium falciparum in isolates from Tanzania without evidence of an association to clinical sulfadoxine/pyrimethamine resistance. Jelinek T, Ronn AM, Curtis J, Duraisingh MT, Lemnge MM, Mhina J, Bygbjerg IC, Warhurst DC, Trop Med Int Health 1997 2 1075 1079 10.1046/j.1365-3156.1997.d01-189.x 9391510 (Pubitemid 27505241)
18. PCR-allele-specific restriction analysis (ASRA): protocols for Plasmodium falciparum drug resistance mutation analyses. University of Mayland School of Medicine, University of Mayland 2002 Accessed:10-5-2013
19. Molecular surveillance of drug-resistance associated mutations of Plasmodium falciparum in south-west Tanzania. Schonfeld M, Barreto MI, Schunk M, Maduhu I, Maboko L, Hoelscher M, Berens-Riha N, Kitua A, Loscher T, Malar J 2007 6 2 10.1186/1475-2875-6-2 17224049 (Pubitemid 46169629)
20. Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, Kironde F, Swedberg G, Malar J 2012 11 58 10.1186/1475-2875-11-58 22369089
21. Plasmodium falciparum mutant haplotype infection during pregnancy associated with reduced birthweight, Tanzania. Minja DT, Schmiegelow C, Mmbando B, Bostrom S, Oesterholt M, Magistrado P, Pehrson C, John D, Salanti A, Luty AJ, Lemnge M, Theander T, Lusingu J, Alifrangis M, Emerg Infect Dis 2013 19 doi: 10.3201
22. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the 581G mutation in the P. falciparum dihydropteroate synthase gene. Alifrangis M, Lusingu JP, Mmbando B, Dalgaard MB, Vestergaard LS, Ishengoma D, Khalil IF, Theander TG, Lemnge MM, Bygbjerg IC, Am J Trop Med Hyg 2009 80 523 527 19346369
23. The evolution of pyrimethamine resistant dhfr in Plasmodium falciparum of south-eastern Tanzania: comparing selection under SP alone vs SP + artesunate combination. Malisa AL, Pearce RJ, Mutayoba BM, Abdullah S, Mshinda H, Kachur PS, Bloland P, Roper C, Malar J 2011 10 317 10.1186/1475-2875-10-317 22029848
24. A community-randomized evaluation of the effect of intermittent preventive treatment in infants on antimalarial drug resistance in southern Tanzania. Pearce RJ, Ord R, Kaur H, Lupala C, Schellenberg J, Shirima K, Manzi F, Alonso P, Tanner M, Mshinda H, Roper C, Schellenberg D, J Infect Dis 2013 207 848 859 10.1093/infdis/jis742 23225897
25. Temporal trends of sulphadoxine-pyrimethamine (SP) drug-resistance molecular markers in Plasmodium falciparum parasites from pregnant women in western Kenya. Iriemenam NC, Shah M, Gatei W, van Eijk AM, Ayisi J, Kariuki S, Vanden EJ, Owino SO, Lal AA, Omosun YO, Otieno K, Desai M, ter Kuile FO, Nahlen B, Moore J, Hamel MJ, Ouma P, Slutsker L, Shi YP, Malar J 2012 11 134 10.1186/1475-2875-11-134 22540158
26. Five years of large-scale dhfr and dhps mutation surveillance following the phased implementation of artesunate plus sulfadoxine-pyrimethamine in Maputo Province, Southern Mozambique. Raman J, Little F, Roper C, Kleinschmidt I, Cassam Y, Maharaj R, Barnes KI, Am J Trop Med Hyg 2010 82 788 794 10.4269/ajtmh.2010.09-0401 20439956
27. [Prevalence of Plasmodium falciparum, anemia and molecular markers of chloroquine and sulfadoxine-pyrimethamine resistance in delivered women in Fana, Mali] (in French). Doumbo S, Ongoiba OA, Doumtabe D, Dara A, Ouologuem TD, Kayentao K, Djimde A, Traore B, Doumbo OK, Bull Soc Pathol Exot 2013 106 188 192 10.1007/s13149-013-0301-1 23893800
28. Surveillance of molecular markers of Plasmodium falciparum resistance to sulphadoxine-pyrimethamine 5 years after the change of malaria treatment policy in Ghana. Duah NO, Quashie NB, Abuaku BK, Sebeny PJ, Kronmann KC, Koram KA, Am J Trop Med Hyg 2012 87 996 1003 10.4269/ajtmh.2012.12-0202 23045251
29. Selection of antimalarial drug resistance after intermittent preventive treatment of infants and children (IPTi/c) in Senegal. Ndiaye M, Tine R, Faye B, Ndiaye JL, Diouf I, Lo AC, Sylla K, Dieng Y, Hallett R, Alifrangis M, Gaye O, C R Biol 2013 336 295 300 10.1016/j.crvi.2013.04.016 23916206
30. Efficacy of sulphadoxine-pyrimethamine with or without artesunate for the treatment of uncomplicated Plasmodium falciparum malaria in southern Mozambique: a randomized controlled trial. Allen EN, Little F, Camba T, Cassam Y, Raman J, Boulle A, Barnes KI, Malar J 2009 8 141 10.1186/1475-2875-8-141 19558654
31. Effectiveness of intermittent preventive treatment with sulfadoxine-pyrimethamine during pregnancy on maternal and birth outcomes in Machinga district, Malawi. Gutman J, Mwandama D, Wiegand RE, Ali D, Mathanga DP, Skarbinski J, J Infect Dis 2013 208 907 916 10.1093/infdis/jit276 23801600
32. Antenatal receipt of sulfadoxine-pyrimethamine does not exacerbate pregnancy-associated malaria despite the expansion of drug-resistant Plasmodium falciparum: clinical outcomes from the QuEERPAM study. Taylor SM, Antonia AL, Chaluluka E, Mwapasa V, Feng G, Molyneux ME, ter Kuile FO, Meshnick SR, Rogerson SJ, Clin Infect Dis 2012 55 42 50 10.1093/cid/cis301 22441649
33. Malaria prevention in pregnancy, birthweight, and neonatal mortality: a meta-analysis of 32 national cross-sectional datasets in Africa. Eisele TP, Larsen DA, Anglewicz PA, Keating J, Yukich J, Bennett A, Hutchinson P, Steketee RW, Lancet Infect Dis 2012 12 942 949 10.1016/S1473-3099(12)70222-0 22995852
34. Malaria Policy Advisory Committee to the WHO: conclusions and recommendations of March 2013 meeting. WHO-MPAC, Malar J 2013 12 213 23787092
35. Increased prevalence of dhfr and dhps mutants at delivery in Malawian pregnant women receiving intermittent preventive treatment for malaria. Lin JT, Mbewe B, Taylor SM, Luntamo M, Meshnick SR, Ashorn P, Trop Med Int Health 2013 18 175 178 10.1111/tmi.12028 23198734
36. Return of chloroquine antimalarial efficacy in Malawi. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, N Engl J Med 2006 355 1959 1966 10.1056/NEJMoa062032 17093247 (Pubitemid 44708015)
37. Trends in chloroquine resistance marker, Pfcrt-K76T mutation ten years after chloroquine withdrawal in Tanzania. Mohammed A, Ndaro A, Kalinga A, Manjurano A, Mosha JF, Mosha DF, van ZM, Koenderink JB, Mosha FW, Alifrangis M, Reyburn H, Roper C, Kavishe RA, Malar J 2013 12 415 10.1186/1475-2875-12-415 24225406
38. Patterns of chloroquine use and resistance in sub-Saharan Africa: a systematic review of household survey and molecular data. Frosch AE, Venkatesan M, Laufer MK, Malar J 2011 10 116 10.1186/1475-2875-10-116 21554692